Advertisement

Advertisement

NRXP Stock Latest News

Psychedelic: Psyence BioMed announces exclusive U.S. ibogaine license

The FlyPsychedelic: Psyence BioMed announces exclusive U.S. ibogaine license

NRx Pharmaceuticals awarded initial $11.18M DARPA prime contract

PremiumThe Fly

NRx Pharmaceuticals awarded initial $11.18M DARPA prime contract

1d ago

NRX Pharmaceuticals Gains FDA Boost for Ketamine Review

PremiumCompany Announcements

NRX Pharmaceuticals Gains FDA Boost for Ketamine Review

15d ago

NRx Pharmaceuticals says FDA reclassifies ANDA amendment to ‘minor’

PremiumThe Fly

NRx Pharmaceuticals says FDA reclassifies ANDA amendment to ‘minor’

16d ago

NRx Pharmaceuticals Enhances Investor Outreach with Updated Presentation

PremiumCompany Announcements

NRx Pharmaceuticals Enhances Investor Outreach with Updated Presentation

17d ago

Psychedelic: Enveric, Helus, Bright Minds report earnings results

PremiumThe FlyPsychedelic: Enveric, Helus, Bright Minds report earnings results

1M ago

Nrx Pharmaceuticals Earnings Call Signals Cautious Momentum

Company Announcements

Nrx Pharmaceuticals Earnings Call Signals Cautious Momentum

1M ago

Psychedelic: Definium’s LSD-based pill meets endpoints in GAD study

The Fly

Psychedelic: Definium’s LSD-based pill meets endpoints in GAD study

2M ago

NRXP Earnings this Week: How Will it Perform?

PremiumPre-Earnings

NRXP Earnings this Week: How Will it Perform?

2M ago

NRx Advances FDA Review of Ketamine ANDA Packaging Issue

PremiumCompany Announcements

NRx Advances FDA Review of Ketamine ANDA Packaging Issue

2M ago

FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA

PremiumThe Fly

FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA

2M ago

Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences

PremiumThe Fly

Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences

2M ago

NRx Defense Systems Advances DARPA-Backed Depression Trial

PremiumCompany AnnouncementsNRx Defense Systems Advances DARPA-Backed Depression Trial

2M ago

NRx Pharmaceuticals issues response to Kadima statements

The Fly

NRx Pharmaceuticals issues response to Kadima statements

3M ago

Psychedelic: Definium soars on study results for LSD-based depression treatment

The Fly

Psychedelic: Definium soars on study results for LSD-based depression treatment

3M ago

Kadima Neuropsychiatry Institute alleges NRx breached contract

PremiumThe Fly

Kadima Neuropsychiatry Institute alleges NRx breached contract

3M ago

ZETA announces treatment of first patient with Zeta TMS Navigation System

PremiumThe Fly

ZETA announces treatment of first patient with Zeta TMS Navigation System

3M ago

Thomas Shrader Reiterates Buy on NRXP, Maintains $25 Price Target on NRX-100/101 FDA and RWE-Driven Upside

PremiumRatings

Thomas Shrader Reiterates Buy on NRXP, Maintains $25 Price Target on NRX-100/101 FDA and RWE-Driven Upside

3M ago

NRx Pharmaceuticals announces FDA grant of expanded access protocol for NRX-101

PremiumThe Fly

NRx Pharmaceuticals announces FDA grant of expanded access protocol for NRX-101

3M ago

Psychedelic: Optimi Health completes psilocybin export to the UK

PremiumThe FlyPsychedelic: Optimi Health completes psilocybin export to the UK

4M ago

NRx Pharmaceuticals Announces $20 Million Public Stock Offering

Company Announcements

NRx Pharmaceuticals Announces $20 Million Public Stock Offering

4M ago

NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50

The Fly

NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >